22 May 2013
Keywords: high, dose, faslodex, impresses, breast, cancer, trial
Article | 24 December 2007
New data presented at this year's San Antonio Breast Cancer Symposium indicate that a high-dose regimen of Faslodex (fulvestrant)
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
24 December 2007
17 December 2007
21 May 2013
© 2013 thepharmaletter.com